Scantox, a contract research organization (CRO), has developed a significant footprint in toxicology and preclinical lead optimization over the past few decades. By leveraging scientific expertise and a flexible service model, Scantox has remained at the forefront of innovation, providing tailored solutions to meet the evolving needs of a diverse client base.

Our services support a broad spectrum of preclinical drug development elements. From lead optimization within in vitro and in vivo efficacy models, formulation development, regulatory toxicology studies incl. supportive functions as clinical pathology, bioanalysis, histology all the way to manufacturing and distribution of products for clinical trial phase 1 and 2. This enables clients to progress their development projects under one roof in a trustworthy collaborative matter based on the highest technical and scientific standards.

Our client base ranges from Start-ups, to pharmaceutical companies of all sizes, biotechs and CDMOs.